Salama Ahmed M, Hardy John G, Yessuf Abdurohman Mengesha, Chen Jianbin, Ni Ming, Huang Cheng, Zhang Qidong, Liu Yong
State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing 100029, China.
Department of Chemistry, Lancaster University, Lancaster LA1 4YB, U.K.
ACS Appl Bio Mater. 2025 Apr 21;8(4):2691-2715. doi: 10.1021/acsabm.4c01968. Epub 2025 Apr 7.
Injectable hydrogels represent a highly promising approach for localized drug delivery systems (DDSs) in the management of bone-related conditions such as osteoporosis, osteonecrosis, osteoarthritis, osteomyelitis, and osteosarcoma. Their appeal lies in their biocompatibility, adjustable mechanical properties, and capacity to respond to external stimuli, including pH, temperature, light, redox potential, ionic strength, and enzymatic activity. These features enable enhanced targeted delivery of bioactive agents. This mini-review evaluates the synthesis of injectable hydrogels as well as recent advancements for treating a range of bone disorders, focusing on their mechanisms as localized and sustained DDSs for delivering drugs, nanoparticles, growth factors, and cells (e.g., stem cells). Moreover, it highlights their clinical studies for bone disease treatment. Additionally, it emphasizes the potential synergy between injectable hydrogels and hydrogel-based point-of-care technologies, which are anticipated to play a pivotal role in the future of bone disease therapies. Injectable hydrogels have the potential to transform bone disease treatment by facilitating precise, sustained, and minimally invasive therapeutic delivery. Nevertheless, significant challenges, including long-term biocompatibility, scalability, reproducibility, and precise regulation of drug release kinetics, must be addressed to unlock their clinical potential fully. Addressing these challenges will not only advance bone disease therapy but also open new avenues in regenerative medicine and personalized healthcare.
可注射水凝胶是用于治疗骨质疏松症、骨坏死、骨关节炎、骨髓炎和骨肉瘤等骨相关疾病的局部给药系统（DDS）中一种极具前景的方法。它们的吸引力在于其生物相容性、可调节的机械性能以及对外部刺激（包括pH值、温度、光、氧化还原电位、离子强度和酶活性）的响应能力。这些特性能够增强生物活性剂的靶向递送。本综述评估了可注射水凝胶的合成以及治疗一系列骨疾病的最新进展，重点关注其作为局部和持续给药系统用于递送药物、纳米颗粒、生长因子和细胞（如干细胞）的机制。此外，还强调了它们在骨疾病治疗方面的临床研究。此外，它强调了可注射水凝胶与基于水凝胶的即时护理技术之间的潜在协同作用，预计这将在骨疾病治疗的未来发挥关键作用。可注射水凝胶有潜力通过促进精确、持续和微创的治疗递送来改变骨疾病的治疗。然而，必须解决包括长期生物相容性、可扩展性、可重复性以及药物释放动力学的精确调节等重大挑战，以充分释放其临床潜力。应对这些挑战不仅将推动骨疾病治疗的发展，还将为再生医学和个性化医疗开辟新途径。
